EMA Authorised: Glyxambi (empagliflozin;linagliptin) — Boehringer Ingelheim International GmbH

View source ↗

Summary

The EMA authorised Glyxambi, a fixed-dose combination of empagliflozin and linagliptin, for the treatment of Type 2 diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• GLYXAMBI (empagliflozin and linagliptin)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Boehringer Ingelheim International GmbH. Decision date: 28/03/2026